Soligenix Completes Phase 2a Study for SGX945

Soligenix ( (SNGX) ) has shared an announcement.

On July 31, 2025, Soligenix announced the completion of its Phase 2a proof of concept study for SGX945 (dusquetide) in treating Behçet’s Disease, demonstrating biological efficacy. The study showed that SGX945 achieved a 40% improvement in oral ulcers compared to placebo, with sustained benefits even after treatment stopped at Week 4, unlike the continuously administered apremilast. SGX945 was well-tolerated without the adverse effects seen in apremilast, such as diarrhea and nausea. This development positions Soligenix to further explore SGX945’s potential in treating Behçet’s Disease and other inflammatory conditions, aiming to enhance patient outcomes and expand market presence.

The most recent analyst rating on (SNGX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Soligenix stock, see the SNGX Stock Forecast page.

Spark’s Take on SNGX Stock

According to Spark, TipRanks’ AI Analyst, SNGX is a Underperform.

Soligenix’s overall stock score is primarily driven by its weak financial performance, characterized by declining revenues and persistent losses. While the technical analysis indicates some potential for short-term stability, the valuation and financial metrics suggest ongoing challenges. The company’s recent loan repayment is a positive step towards financial flexibility, but it does not alleviate the underlying financial and operational issues.

To see Spark’s full report on SNGX stock, click here.

More about Soligenix

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.

Average Trading Volume: 919,695

Technical Sentiment Signal: Strong Sell

Current Market Cap: $4.15M

For an in-depth examination of SNGX stock, go to TipRanks’ Overview page.